Replies to post #105914 on Biotech Values

[jq1234]

FDA pulled Meridia, left Avandia on the market. It shows they consider obesity drugs have higher bar to clear than diabetes drugs.

[AlpineBV_Miller]

Agreed. Characterized by limited patient populations difficult to expand "off label" and clear benefit to risk.

If anyone comes up with a genetically-targeted obesity drug combined with a biomarker screen for the target, I'd be interested. Until then, it's smarter money to bet against all of them.